BTC$77,213▼ 0.39%
ETH$2,116▼ 0.78%
SOL$85.65▲ 0.78%
HYPE$57.73▲ 15.29%
XRP$1.36▼ 0.53%
BNB$649.20▲ 0.73%
DOGE$0.1045▲ 0.50%
AVAX$9.31▲ 0.70%
LINK$9.58▼ 0.12%
TAO$278.80▲ 5.59%
ZEC$661.59▲ 13.74%
NEAR$1.76▲ 7.73%
BTC$77,213▼ 0.39%
ETH$2,116▼ 0.78%
SOL$85.65▲ 0.78%
HYPE$57.73▲ 15.29%
XRP$1.36▼ 0.53%
BNB$649.20▲ 0.73%
DOGE$0.1045▲ 0.50%
AVAX$9.31▲ 0.70%
LINK$9.58▼ 0.12%
TAO$278.80▲ 5.59%
ZEC$661.59▲ 13.74%
NEAR$1.76▲ 7.73%
RSS
Follow-Up ·

The Cancer Vaccine (INTISMERAN) Has $10,255 of Liquidity Left Since We Covered It

What Happened

The Cancer Vaccine (INTISMERAN) currently has a liquidity of $10,255. This marks a significant decline from the $54,066 liquidity reported when this site covered it on August 19, 2026.

INTISMERAN price chart, 65 candles to Aug 22, 2026
TA · Downtrend — price below EMA-20 and EMA-50 · RSI 25 (oversold) · near the bottom of its range · liquidity $10.3k · pool 3d old
Snapshot captured
What the model flagged, and what happened scored 67.8/100 Elevated at coverage

Liquidity measured $10,255 against $54,066 at coverage — down 81.0%. Measured against The Cancer Vaccine (INTISMERAN) Records Elevated Volume Relative to Market Cap on Robinhood.

  • Volume vs liquidity103.2xBorne out
    Flagged because turnover far above pool size meant exits would move the price.
  • Pair maturity1.2 hoursBorne out
    Flagged because a pair this new had no trading history to stand on.
  • Liquidity lock34.7% lockedBorne out
    Flagged because an unlocked pool could be withdrawn.
  • Liquidity depth$89,171Borne out
    Flagged because a pool this thin would not absorb exits.
Never visible to the model
  • Team identity, track record, and off-chain commitments
  • Whether locked liquidity unlocks soon — only the current lock state is read
  • Coordinated wallets that spread supply to look decentralised
  • Social-media manipulation and paid promotion
  • Anything in a contract's logic beyond the standard checks performed

This is one token measured against its own coverage. It is not evidence the score is predictive — a token failing does not prove the coverage was right, and one surviving does not prove it was wrong. These follow-ups are only written when a pool has collapsed, so flags will tend to read as borne out here; that is a property of which tokens get a follow-up, not a measure of how often the model is right. The corpus-wide test, covering every token including those that survived, is on the track record. Not financial advice.

Token
This article has no stored risk assessment. The token page carries a live assessment and every article published about INTISMERAN.
Risk assessment and coverage for INTISMERAN →

What We Said At The Time

In our original article published on August 19, 2026, titled "The Cancer Vaccine (INTISMERAN) Records Elevated Volume Relative to Market Cap on Robinhood," we assessed the token's risk band as Elevated, with a risk score of 67.8. The findings highlighted concerns regarding its liquidity relative to market cap.

What This Shows

The current liquidity figures indicate a severe degradation in the token's market conditions since our last coverage. The decline from $54,066 to $10,255 underscores the challenges flagged originally regarding liquidity management and market stability.

Current State

  • Liquidity at publication: $54,066
  • Current liquidity: $10,255
  • Last checked: August 22, 2026

Risk Note

This article does not constitute financial advice.